SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

References

• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2015381140 14925538310
   PubMed Web of Science ®Google Scholar
• de Pablos-VelascoPParhoferKGBradleyCCurrent level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA studyClin Endocrinol (Oxf)201480147 5623194193
   PubMed Web of Science ®Google Scholar
• FonsecaVADefining and characterizing the progression of type 2 diabetesDiabetes Care200932Suppl 2S151 S15619875543
   PubMed Web of Science ®Google Scholar
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 3. 2013, zuletzt geändert: April 2014. [National Patient-Centered Guideline: Therapy of Type 2 Diabetes – Long Version, 1. Edition, Version 3. 2013, latest adaptation: April 2014]10.6101/AZQ/000203 Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapieAccessed November 19, 2014 German
   Google Scholar
• SarwarNGaoPSeshasaiSRDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesLancet201037597332215 222220609967
   PubMed Web of Science ®Google Scholar
• HaunerHHanischJBramlagePPrevalence of undiagnosed type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)Exp Clin Endocrinol Diabetes2008116118 2517926235
   PubMed Web of Science ®Google Scholar
• BertholdHKGouni-BertholdIBestehornKKardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland – ein Versorgungsparadox. [Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Germany]Dtsch Arztebl2007104A861 867 German
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983529131854 8659742977
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536694931279 128916214598
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317 132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327 133523992602
   PubMed Web of Science ®Google Scholar
• BaysHFrom victim to ally: the kidney as an emerging target for the treatment of diabetes mellitusCurr Med Res Opin2009253671 68119232040
   PubMed Web of Science ®Google Scholar
• RahmouneHThompsonPWWardJMSmithCDHongGBrownJGlucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetesDiabetes200554123427 343416306358
   PubMed Web of Science ®Google Scholar
• INVOKANA™ (canagliflozin) tablets, for oral use [summary of product characteristics]Beerse, BelgiumJanssen-Cilag International NV2015
   Google Scholar
• ShaSPolidoriDFarrellKPharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover studyDiabetes Obes Metab2015172188 19725421015
   PubMed Web of Science ®Google Scholar
• PolidoriDShaSMudaliarSCanagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDiabetes Care20133682154 216123412078
   PubMed Web of Science ®Google Scholar
• FerranniniEMuscelliEFrascerraSMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJ Clin Invest20141242499 50824463454
   PubMed Web of Science ®Google Scholar
• LiangYArakawaKUetaKEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsPLoS One201272e3055522355316
   PubMed Web of Science ®Google Scholar
• ShaSDevineniDGhoshACanagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes Obes Metab2011137669 67221457428
   PubMed Web of Science ®Google Scholar
• NomuraSSakamakiSHonguMDiscovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitusJ Med Chem201053176355 636020690635
   PubMed Web of Science ®Google Scholar
• SeufertJSGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetesDtsch Med Wochenschr2014139Suppl 2S52 S5824481633
   PubMed Web of Science ®Google Scholar
• EhrenkranzJRLewisNGKahnCRRothJPhlorizin: a reviewDiabetes Metab Res Rev200521131 3815624123
   PubMed Web of Science ®Google Scholar
• FORXIGA™ (dapagliflozin) 5 mg and 10 mg film-coated tablets [summary of product characteristics]Middlesex, UKBristol-Myers Squibb/AstraZeneca EEIG2014
   Google Scholar
• JARDIANCE™ (empagliflozin) 10 mg film-coated tablets [summary of product characteristics]Ingelheim, GermanyBoehringer Ingelheim GmbH2014
   Google Scholar
• NealBPerkovicVde ZeeuwDRationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trialAm Heart J20131662217 22323895803
   PubMed Web of Science ®Google Scholar
• BodeBStenlöfKSullivanDFungAUsiskinKEfficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trialHosp Pract (1995)201341272 8423680739
   PubMedGoogle Scholar
• LeiterLAYoonKHAriasPCanagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 studyDiabetes Care2015383355 36425205142
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet20133829896941 95023850055
   PubMed Web of Science ®Google Scholar
• ForstTGuthrieRGoldenbergREfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneDiabetes Obes Metab2014165467 47724528605
   PubMed Web of Science ®Google Scholar
• Lavalle-GonzálezFJJanuszewiczADavidsonJEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia201356122582 259224026211
   PubMed Web of Science ®Google Scholar
• NealBPerkovicVde ZeeuwDEfficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesDiabetes Care2015383403 41125468945
   PubMed Web of Science ®Google Scholar
• SchernthanerGGrossJLRosenstockJCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trialDiabetes Care20133692508 251523564919
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKALong-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M studyCurr Med Res Opin2014302163 17524073995
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab2013154372 38223279307
   PubMed Web of Science ®Google Scholar
• BodeBStenlöfKHarrisSLong-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetesDiabetes Obes Metab2015173294 30325495720
   PubMed Web of Science ®Google Scholar
• GilbertREWeirMRFiorettoPLawGUsiskinKMeningerGEffect of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) based on age and estimated glomerular filtration rate (eGFR) [abstract]Diabetes2014Suppl 1A212 A343 Abstract 1034-P
   Google Scholar
• BasileJNThe potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)J Diabetes Complications2013273280 28623375850
   PubMed Web of Science ®Google Scholar
• NealBMatthewsDFulcherG52-week effects of canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), added to insulin therapy in type 2 diabetes (T2D) Poster presented at: 22nd Biennial World Diabetes Congress of the International Diabetes Federation (IDF) December 2–6, 2013 Melbourne, Australia
   Google Scholar
• FerranniniECushmanWCDiabetes and hypertension: the bad companionsLancet20123809841601 61022883509
   PubMed Web of Science ®Google Scholar
• MatthaeiSCanagliflozin monotherapy: clinical study data in type 2 diabetes mellitusDtsch Med Wochenschr2014139Suppl 2S59 S6424481634
   PubMed Web of Science ®Google Scholar
• WilkeTAhrendtPSchwartzDLinderRAhrensSVerheyenFIncidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patientsDtsch Med Wochenschr2013138369 7523299340
   PubMed Web of Science ®Google Scholar
• WeirMJanuszewiczAGilbertREffect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitusJ Clin Hypertens (Greenwich)20141612875 88225329038
   PubMed Web of Science ®Google Scholar
• UsiskinKKlineIFungAMayerCMeiningerGSafety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study resultsPostgrad Med2014126316 3424918789
   PubMed Web of Science ®Google Scholar
• WeidmannPde CourtenMFerrariPEffect of diuretics on the plasma lipid profileEur Heart J199213Suppl G61 671486908
   PubMed Web of Science ®Google Scholar
• PloskerGLCanagliflozin: a review of its use in patients with type 2 diabetes mellitusDrugs2014747807 82424831734
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP)Assessment Report Canagliflozin. EMA/374133/20139 192013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdfAccessed November 19, 2014
   Google Scholar
• AmirJWaiteMToblerJThe role of hyperglycemia in mechanisms of exacerbated inflammatory responses within the oral cavityCell Immunol2011272145 5221996642
   PubMed Web of Science ®Google Scholar
• NicolleLECapuanoGFungAUsiskinKUrinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitorPostgrad Med201412617 1724393747
   PubMed Web of Science ®Google Scholar
• NyirjesyPSobelJDFungAGenital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesCurr Med Res Opin20143061109 111924517339
   PubMed Web of Science ®Google Scholar
• MikhailNSafety of canagliflozin in patients with type 2 diabetesCurr Drug Saf201492127 13224446889
   PubMedGoogle Scholar